Evidence Snapshot

Tyrosine-protein kinase JAK1

CHEMBL2835 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:12Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 4:51 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL2835

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tyrosine-protein kinase JAK1 as ChEMBL target CHEMBL2835, mapped to UniProt P23458. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Tyrosine-protein kinase JAK1

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL2835

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P23458

Tyrosine-protein kinase JAK1

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Tyrosine-protein kinase JAK1 matters

As of 2026-09-13

Tyrosine-protein kinase JAK1 is reviewed as Tyrosine-protein kinase JAK1 (UniProt P23458); Tyrosine-protein kinase JAK1 shows approved-linked disease relevance led by rheumatoid arthritis. 5 more disease programs remain visible in the same review block.; 6 linked drugs keep this evidence frame grounded.; the current evidence base includes 37 approved drugs, 14221 compounds, and 1194 assays, with lead potency reaching pChEMBL 11.0.

Protein context

Tyrosine-protein kinase JAK1

Tyrosine-protein kinase JAK1 Sequence length is 1154 aa.

Review this target as Tyrosine-protein kinase JAK1, mapped to UniProt P23458. Sequence length is 1154 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P23458 Protein

Disease context

rheumatoid arthritis

Tyrosine-protein kinase JAK1 shows approved-linked disease relevance led by rheumatoid arthritis. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BARICITINIB, FILGOTINIB, FILGOTINIB MALEATE.

Start review with rheumatoid arthritis because it currently carries approved-linked support. Linked drugs include BARICITINIB, FILGOTINIB, FILGOTINIB MALEATE, INCB-047986. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 6 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 37 approved drugs, 14221 compounds, and 1194 assays for this target. The dominant activity type is IC50. CHEMBL5945428 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL5945428 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine

37 approved pChEMBL 11.0

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Tyrosine-protein kinase JAK1 matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P23458, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why rheumatoid arthritis is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

14221

Total Compounds

1194

Total Assays

Approved Drugs

IC50: 14941.0, KI: 3877.0, EC50: 443.0, KD: 579.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL5945428	11.0	IC50	—
No preferred name CHEMBL3896068	11.0	IC50	—
No preferred name CHEMBL6031741	11.0	IC50	—
No preferred name CHEMBL6017191	11.0	IC50	—
No preferred name CHEMBL5942656	11.0	IC50	—

Approved Drugs

Structure	Compound	First Approval
	MOMELOTINIB CHEMBL1078178	2023
	DEUCRAVACITINIB CHEMBL4435170	2022
	PACRITINIB CHEMBL2035187	2022
	ABROCITINIB CHEMBL3655081	2021
	FILGOTINIB CHEMBL3301607	2020
	FEDRATINIB CHEMBL1287853	2019
	ENTRECTINIB CHEMBL1983268	2019
	PEFICITINIB CHEMBL3137308	2019
	UPADACITINIB CHEMBL3622821	2019
	MIDOSTAURIN CHEMBL608533	2017
	BARICITINIB CHEMBL2105759	2017
	NINTEDANIB CHEMBL502835	2014
	TOFACITINIB CHEMBL221959	2012
	TOFACITINIB CITRATE CHEMBL2103743	2012
	PONATINIB CHEMBL1171837	2012
	RUXOLITINIB PHOSPHATE CHEMBL1795071	2011
	RUXOLITINIB CHEMBL1789941	2011
	CRIZOTINIB CHEMBL601719	2011
	SUNITINIB CHEMBL535	2006

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:12Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 4:51 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL2835